Phase I and pharmacokinetics (PK) study of RPR 116258A given as a weekly 1-hour infusion at day 1, day 8, day 15, day 22 every 5 weeks in patients (pts) with advanced solid tumors.

被引：0

作者：

Fumoleau, P

Trigo, J

Campone, M

Baselga, J

Sistac, F

Gimenez, P

Manos, L

Fontaine, H

Semiond, D

Sanderink, G

Perard, D

Besenval, M

机构：

[1] Ctr Rene Gauducheau, F-44035 Nantes, France

[2] Hosp Gen Valle Hebron, Barcelona, Spain

[3] Aventis Pharma Spain, Barcelona, Spain

[4] Aventis Pharma France, Antony, France

[5] Aventis Pharma France, Alforville, France

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

282

引用

页码：3710S / 3710S

页数：1